GLOW
Multi peptide
ABOUT
GLOW is a vendor-assembled three-peptide blend, most commonly sold as a 70 mg vial of GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. Totals and ratios differ between suppliers; it is KLOW without the KPV.
WHAT IS IN IT · 3 COMPOUNDS
Check the amounts on the vial rather than assuming them from the blend name.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
The same three repair-adjacent mechanisms KLOW carries, minus the anti-inflammatory tripeptide. GHK-Cu binds copper and has been reported to modulate collagen and gene expression in laboratory work; BPC-157 is credited with angiogenesis and cytoprotection in rodent models; TB-500 is a synthetic fragment of the actin-sequestering protein thymosin beta-4. The proposed division of labour - collagen, blood supply, cell migration - is a vendor rationale, not a demonstrated mechanism of the combination.
PHARMACOKINETICS
No component has a published human pharmacokinetic profile, and vendor totals for this blend range from 10 mg to 70 mg per vial at differing ratios, so two products under the same name are not necessarily the same exposure.
REVIEW
PUBLISHED PAIR RECORDS
with GHK-Cu
Same substance taken twice: blend already contains this compoundGLOW already contains GHK-Cu at 50 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with BPC-157
Same substance taken twice: blend already contains this compoundGLOW already contains BPC-157 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with TB-500
Same substance taken twice: blend already contains this compoundGLOW already contains TB-500 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with KLOW
Overlapping blends: the same compounds appear in bothKLOW and GLOW both contain GHK-Cu, BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Wolverine blend
Overlapping blends: the same compounds appear in bothGLOW and Wolverine blend both contain BPC-157, TB-500. Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Thymosin Beta-4
Inherited from a component of this blendGLOW contains BPC-157 and TB-500, and the catalogue holds a curated pair record between those components and Thymosin Beta-4: BPC-157 (commonly combined tissue-repair peptides with no combination evidence); TB-500 (same molecule family: fragment and parent protein). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
No study has examined this blend as a blend. A PubMed search for the product name returns no matching literature, so everything known about it is inference from its separate components, and the effect of giving them together at a fixed ratio is uncharacterised rather than known to be additive. The component evidence is thin in the same way KLOW's is: one uncontrolled BPC-157 chart review, and a small randomised study of topical GHK-Cu on laser-resurfaced skin that did not show objective improvement in its main outcomes.
REPORTED EFFECTS
No safety data exists for the blend. BPC-157 and thymosin beta-4 fragments are on FDA's Category 2 interim compounding list, as is injectable-route GHK-Cu. Thymosin beta-4 and its derivatives are prohibited at all times in sport.
RESEARCH LIMITATIONS
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CURATED SOURCES · 5